Funding
← Back to your selection

Mission BioCapital

Activity from announced rounds

All recorded activity

Mission BioCapital is the manager whose Platinum Program portfolio includes Enodia and Cloverleaf.

Recorded funding activity

Enodia develops medicines that degrade proteins during synthesis. Cloverleaf engineers transfer RNA for cancer therapies, while EpiBiologics develops antibodies for extracellular-protein degradation. The manager remains distinct from named funds and programs.

Sources
Rounds participated in
4
Confirmed lead rounds
1
2 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$240.8M
4 disclosed · full round size, not this investor’s share

By stage

Seed2
Series A1
Series B1

By primary sector

Biotech4

By country

United States2
Denmark1
France1

Rounds

4 in all activity
Cloverleaf Bio

Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.

$33MSeed
Participant
Enodia Therapeutics

Develops small-molecule therapies for targeted protein degradation at the point of synthesis

Role not disclosed
EpiBiologics

Develops bispecific antibodies for targeted degradation of extracellular proteins.

$107MSeries B
Role not disclosed